Clin Nutr Res.  2019 Jul;8(3):209-218. 10.7762/cnr.2019.8.3.209.

The Effect of Arginine Intake on Colorectal Cancer: a Systematic Review of Literatures

• Karimian J
• Hadi A
• Salehi-sahlabadi A
• Kafeshani

• KMID: 2454078
• DOI: http://doi.org/10.7762/cnr.2019.8.3.209

Abstract

Colorectal cancer (CRC) is one of the major reasons of mortality in the worldwide. There is clear evidence that some amino acids such as arginine can improve CRC and its complications. Hence, in this systematic review we evaluated the association between arginine intake and CRC improvement. We searched the PubMed, Scopus, ISI Web of Science, Cochrane library, and Google Scholar databases by using proper keywords to find the relevant literatures, published to March 2019. Nine human studies of 523 screened articles were included in present systematic review. The majority of studies have found a positive association between consumption of arginine and CRC improvement. Increased inducible nitric oxide (NO) synthase expression and subsequently increasing the NO concentration in the tumor and/or serum, after arginine intake may be responsible for these protective effects. Also, arginine consumption may reduce cell proliferation in CRC and it can enhance immune function after remove the tumor. Although the benefits of arginine consumption in CRC patients were reported in previous trials, the finding need replication in well-designed studies before final conclusion.

Keyword

Arginine; Supplementation; Colorectal cancer; Systematic review

MeSH Terms

Amino Acids
Arginine*
Cell Proliferation
Colorectal Neoplasms*
Humans
Mortality
Nitric Oxide
Amino Acids
Arginine
Nitric Oxide

Figure

• 

  Figure 1 Flow chart of the process of the study selection.

Reference

1. World Health Organization. Cancer fact sheet [Internet]. Geneva: WHO Media Centre;2018. cited 2018 September 13. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.

2. Sung JJ, Lau JY, Goh KL, Leung WK. Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005; 6:871–876.

3. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002; 3:565–574.

4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569–578.

5. Terry P, Giovannucci E, Michels KB, Bergkvist L, Hansen H, Holmberg L, Wolk A. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst. 2001; 93:525–533.

6. Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 2012; 27:613–623.

7. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med. 2008; 34:1980–1990.

8. McCowen KC, Bistrian BR. Immunonutrition: problematic or problem solving? Am J Clin Nutr. 2003; 77:764–770.

9. Gunerhan Y, Koksal N, Sahin UY, Uzun MA, Ekşioglu-Demiralp E. Effect of preoperative immunonutrition and other nutrition models on cellular immune parameters. World J Gastroenterol. 2009; 15:467–472.

10. Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, Carey Satterfield M, Smith SB, Spencer TE, Yin Y. Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009; 37:153–168.

11. Dawson TM, Dawson VL. Nitric oxide signaling in neurodegeneration and cell death. Adv Pharmacol. 2018; 82:57–83.

12. Brankovic B, Stanojevic G, Stojanovic I, Veljkovic A, Kocic G, Janosevic P, Nestorovic M, Petrovic D, Djindjic B, Pavlovic D, Krivokapic Z. Nitric oxide synthesis modulation - a possible diagnostic and therapeutic target in colorectal cancer. J BUON. 2017; 22:162–169.

13. Ma Q, Hoper M, Anderson N, Rowlands BJ. Effect of supplemental L-arginine in a chemical-induced model of colorectal cancer. World J Surg. 1996; 20:1087–1091.

14. Lind DS. Arginine and cancer. J Nutr. 2004; 134:2837S–2841S.

15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6:e1000100.

16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1–12.

17. Wang YJ, Ma QY, Gao XP, Song ZJ. Effect of arginine on the expressions of proliferating cell nuclear antigen and survivin in colorectal tumor. Chin J Clin Nutr. 2006; 6:378–381.

18. Hu X, Zhang Q, Sun D, Guo H, Lang X, Wang T, Liu E. Effect of L-arginine on the tumour cell proliferative activity in patients with colorectal cancer. J China Med Univ. 2001; 5:391–392.

19. Hui J, Gao X, Ma Q, Wang Y. The effects of L-arginine on the cell proliferation in patients with colorectal tumor and its mechanisms. Shaanxi Med J. 2011; 6:666–667. 673

20. Ma Q, Wang Y, Gao X, Ma Z, Song Z. L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin Cancer Res. 2007; 13:7407–7412.

21. Caglayan K, Oner I, Gunerhan Y, Ata P, Koksal N, Ozkara S. The impact of preoperative immunonutrition and other nutrition models on tumor infiltrative lymphocytes in colorectal cancer patients. Am J Surg. 2012; 204:416–421.

22. Finco C, Magnanini P, Sarzo G, Vecchiato M, Luongo B, Savastano S, Bortoliero M, Barison P, Merigliano S. Prospective randomized study on perioperative enteral immunonutrition in laparoscopic colorectal surgery. Surg Endosc. 2007; 21:1175–1179.

23. Braga M, Gianotti L, Vignali A, Carlo VD. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. Surgery. 2002; 132:805–814.

24. Horie H, Okada M, Kojima M, Nagai H. Favorable effects of preoperative enteral immunonutrition on a surgical site infection in patients with colorectal cancer without malnutrition. Surg Today. 2006; 36:1063–1068.

25. Matsuda A, Furukawa K, Takasaki H, Suzuki H, Kan H, Tsuruta H, Shinji S, Tajiri T. Preoperative oral immune-enhancing nutritional supplementation corrects TH1/TH2 imbalance in patients undergoing elective surgery for colorectal cancer. Dis Colon Rectum. 2006; 49:507–516.

26. Zhang W, Meng R, Fu C, Yu D. Gene expression significance of beta-catenin, p53 and PCNA in PJS polyposis. Zhonghua Wai Ke Za Zhi. 2002; 40:104–106.

27. Suh N, Paul S, Hao X, Simi B, Xiao H, Rimando AM, Reddy BS. Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin Cancer Res. 2007; 13:350–355.

28. Kohno H, Suzuki R, Curini M, Epifano F, Maltese F, Gonzales SP, Tanaka T. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. Int J Cancer. 2006; 118:2936–2942.

29. Lim DY, Tyner AL, Park JB, Lee JY, Choi YH, Park JH. Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1. J Cell Physiol. 2005; 205:107–113.

30. Nomoto H, Iigo M, Hamada H, Kojima S, Tsuda H. Chemoprevention of colorectal cancer by grape seed proanthocyanidin is accompanied by a decrease in proliferation and increase in apoptosis. Nutr Cancer. 2004; 49:81–88.

31. Stefanaki K, Rontogiannis D, Vamvouka C, Bolioti S, Chaniotis V, Sotsiou F, Vlychou M, Delidis G, Kakolyris S, Georgoulias V, Kanavaros P. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. Anticancer Res. 1998; 18:1689–1695.

32. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3:917–921.

33. Hirokawa N. Microtubule organization and dynamics dependent on microtubule-associated proteins. Curr Opin Cell Biol. 1994; 6:74–81.

34. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998; 58:5071–5074.

35. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327:524–526.

36. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987; 84:9265–9269.

37. Yim CY, Bastian NR, Smith JC, Hibbs JB Jr, Samlowski WE. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res. 1993; 53:5507–5511.

38. Lala PK. Significance of nitric oxide in carcinogenesis, tumor progression and cancer therapy. Cancer Metastasis Rev. 1998; 17:1–6.

39. Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H. Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat Res. 1997; 379:211–218.

40. Wu G, Meininger CJ. Regulation of nitric oxide synthesis by dietary factors. Annu Rev Nutr. 2002; 22:61–86.

41. Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A. 2003; 100:4843–4848.

42. Shi W, Meininger CJ, Haynes TE, Hatakeyama K, Wu G. Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells. Cell Biochem Biophys. 2004; 41:415–434.

43. Buga GM, Wei LH, Bauer PM, Fukuto JM, Ignarro LJ. NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am J Physiol. 1998; 275:R1256–64.

44. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988; 48:759–774.

45. O'Brien TG. The induction of ornithine decarboxylase as an early, possibly obligatory, event in mouse skin carcinogenesis. Cancer Res. 1976; 36:2644–2653.

46. Gilmour SK, Aglow E, O'Brien TG. Heterogeneity of ornithine decarboxylase expression in 12-O-tetradecanoylphorbol-13-acetate-treated mouse skin and in epidermal tumors. Carcinogenesis. 1986; 7:943–947.

47. Gilmour SK, Verma AK, Madara T, O'Brien TG. Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis. Cancer Res. 1987; 47:1221–1225.

48. Koza RA, Megosh LC, Palmieri M, O'Brien TG. Constitutively elevated levels of ornithine and polyamines in mouse epidermal papillomas. Carcinogenesis. 1991; 12:1619–1625.

49. Lan L, Trempus C, Gilmour SK. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res. 2000; 60:5696–5703.

50. Senkal M, Kemen M, Homann HH, Eickhoff U, Baier J, Zumtobel V. Modulation of postoperative immune response by enteral nutrition with a diet enriched with arginine, RNA, and omega-3 fatty acids in patients with upper gastrointestinal cancer. Eur J Surg. 1995; 161:115–122.

51. Daly JM, Reynolds J, Thom A, Kinsley L, Dietrick-Gallagher M, Shou J, Ruggieri B. Immune and metabolic effects of arginine in the surgical patient. Ann Surg. 1988; 208:512–523.

52. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329:2002–2012.

53. Kudsk KA, Croce MA, Fabian TC, Minard G, Tolley EA, Poret HA, Kuhl MR, Brown RO. Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg. 1992; 215:503–511.